Brokerages predict that Inovio Pharmaceuticals Inc (NASDAQ:INO) will report earnings per share (EPS) of ($0.30) for the current quarter, according to Zacks. Three analysts have issued estimates for Inovio Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.29). Inovio Pharmaceuticals posted earnings per share of ($0.24) in the same quarter last year, which suggests a negative year-over-year growth rate of 25%. The company is scheduled to announce its next quarterly earnings report on Wednesday, March 13th.

According to Zacks, analysts expect that Inovio Pharmaceuticals will report full-year earnings of ($1.04) per share for the current fiscal year, with EPS estimates ranging from ($1.09) to ($0.99). For the next year, analysts expect that the company will post earnings of ($1.08) per share, with EPS estimates ranging from ($1.25) to ($0.94). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.05. Inovio Pharmaceuticals had a negative net margin of 232.58% and a negative return on equity of 72.66%. The business had revenue of $2.00 million during the quarter, compared to analysts’ expectations of $2.20 million. During the same period last year, the company posted ($0.39) EPS.

Several research firms have commented on INO. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday. ValuEngine raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. BidaskClub cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 26th. Finally, Stifel Nicolaus began coverage on shares of Inovio Pharmaceuticals in a research note on Tuesday, October 2nd. They issued a “buy” rating and a $8.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $10.75.

In other Inovio Pharmaceuticals news, CEO Jong Joseph Kim sold 49,060 shares of Inovio Pharmaceuticals stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $5.37, for a total value of $263,452.20. Following the completion of the sale, the chief executive officer now directly owns 2,357,554 shares of the company’s stock, valued at approximately $12,660,064.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.40% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in INO. Levin Capital Strategies L.P. grew its stake in Inovio Pharmaceuticals by 80.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 37,000 shares of the biopharmaceutical company’s stock worth $145,000 after acquiring an additional 16,500 shares during the period. Wellington Shields Capital Management LLC purchased a new stake in Inovio Pharmaceuticals in the 3rd quarter worth approximately $170,000. Emerald Advisers Inc. PA purchased a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at $228,000. Wellington Shields & Co. LLC purchased a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter valued at $267,000. Finally, ING Groep NV purchased a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter valued at $389,000. 31.87% of the stock is owned by hedge funds and other institutional investors.

Shares of INO traded down $0.08 during mid-day trading on Tuesday, reaching $4.84. 592,400 shares of the company’s stock were exchanged, compared to its average volume of 1,058,618. The stock has a market cap of $484.02 million, a price-to-earnings ratio of -4.46 and a beta of 1.88. Inovio Pharmaceuticals has a 52-week low of $3.64 and a 52-week high of $6.30.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Further Reading: Insider Trading – What You Need to Know

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with's FREE daily email newsletter.